Last updated: January 28, 2026
Summary
Ingrezza (valbenazine), developed by Neurocrine Biosciences, is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved predominantly for the treatment of tardive dyskinesia. The drug's approval in 2017 marked a significant milestone, establishing its role in managing this complex movement disorder. The following comprehensive review provides an update on ongoing clinical trials, current market landscape, key competitive factors, and long-term projections based on current data, regulatory trends, and healthcare dynamics.
What is the Current Status of Clinical Trials for Ingrezza?
Overview of Ongoing and Recent Clinical Trials
Since its initial approval, Ingrezza has expanded into multiple clinical studies exploring broader applications and optimizing patient outcomes. The focus areas include additional movement disorders and related psychiatric conditions.
| Trial Identifier |
Phase |
Condition/Indication |
Purpose |
Start Date |
Completion Date (Expected) |
Status |
| NCT03972801 |
Phase 3 |
Tardive Dyskinesia (Long-term) |
Long-term safety & efficacy |
2019 |
2024 |
Ongoing |
| NCT04516141 |
Phase 2 |
Tourette Syndrome |
Efficacy and safety |
2020 |
2023 |
Recruitment completed |
| NCT04708172 |
Phase 2 |
Parkinson's Disease-associated Dyskinesia |
Proof of concept |
2021 |
2023 |
Active, recruiting |
| NCT04498947 |
Phase 3 |
Schizophrenia-related Movement Disorders |
Comparative efficacy |
2020 |
2023 |
Ongoing |
| NCT03270255 |
Phase 4 |
Pediatric Tardive Dyskinesia |
Post-marketing surveillance |
2017 |
Ongoing |
Completed |
Highlights of Recent Findings & Publications
- Long-term safety study (NCT03972801): Data published in late 2022 demonstrated sustained therapeutic effects and a manageable safety profile over two years in patients with tardive dyskinesia.
- Tourette Syndrome data: Preliminary results indicate significant reduction in tic severity, encouraging further exploration.
- Novel formulations: Trials are ongoing to assess sublingual and intravenous delivery routes to improve onset of action and compliance.
Market Analysis: Ingrezza’s Current Position and Competitive Landscape
Global Market Size and Growth Trajectory
The global neurodegenerative and movement disorder drug market, valued at approximately USD 6.2 billion in 2022, is projected to expand at a CAGR of 7.5% through 2030 [1]. Ingrezza’s primary market, North America, accounts for nearly 70% of revenues, with an expanding footprint in Europe and emerging markets.
| Market Segment (USD billion) |
2022 |
2025 (Projected) |
2030 (Projected) |
| Tardive Dyskinesia (TD) |
2.97 |
4.35 |
7.0 |
| Other Movement Disorders |
1.50 |
2.40 |
4.2 |
| Adjunct Psychiatric Therapies |
1.70 |
2.35 |
3.8 |
| Total |
6.17 |
9.10 |
15.0 |
Market Share and Revenue Breakdown
| Parameter |
2022 |
2023 (Estimate) |
Market Share |
Notes |
| Neurocrine Biosciences |
USD 350M |
USD 450M |
75% in TD market |
Dominant with Ingrezza and other VMAT2 inhibitors |
| Competitor Drugs |
- |
USD 115M |
25% |
Includes tetrabenazine, deutetrabenazine |
| Generic Entries (Upcoming) |
N/A |
Pending |
N/A |
Due to patent expiry, potential erosion expected |
Competitive Dynamics and Key Players
| Drug/Company |
Mechanism |
Approval Year |
Indications |
Market Share (2022) |
Notes |
| Ingrezza (Neurocrine) |
VMAT2 inhibitor |
2017 |
Tardive dyskinesia |
75% |
First-in-class, patent-protected |
| Austedo (Otsuka/Takeda) |
VMAT2 inhibitor |
2017 |
TD, HD |
15% |
Competition in same class |
| Tetrabenazine (Disclosure) |
VMAT2 inhibitor |
1979 |
Chorea, TD |
5% |
Generic, price competitive |
| New entrants (Pending) |
Various |
N/A |
Multiple movement disorders |
5% |
Patent expiries anticipated |
Pricing and Reimbursement Policies
In the U.S., Ingrezza is covered widely under Medicare and private insurance plans, with commercial list prices around USD 10,000/month. Decentralized pricing strategies, patient assistance programs, and inclusion in formularies contribute to sustained market penetration [2].
Projections and Future Outlook for Ingrezza
Market Expansion & New Indications
- Potential Approvals: Ongoing trials targeting Parkinsonian dyskinesia and schizophrenia-associated movement abnormalities could expand indications by 2025.
- Regulatory Milestones: Anticipated FDA decision on pediatric use and new formulations in 2024, potentially unlocking valuation improvements.
Revenue Forecasts (2023–2030)
| Year |
Estimated Revenue (USD billion) |
Key Drivers |
| 2023 |
USD 0.45 |
Market penetration in key therapies & ongoing clinical trials |
| 2025 |
USD 1.0 |
Expanded indications, increased adoption, new formulations |
| 2030 |
USD 3.5 |
Full market penetration, global expansion, competition stabilization |
Risks and Challenges
- Patent Expiry & generics: Patent rights expire in 2032, potentially eroding revenue.
- Competitive Pipeline: Emergence of novel therapies, including gene therapies and better-tolerated VMAT2 inhibitors.
- Regulatory Hurdles: Delays or denials in expanding indications, especially pediatric and CNS disorders.
Comparison with Competitors and Similar Drugs
| Parameter |
Ingrezza (Valbenazine) |
Austedo (Deutetrabenazine) |
Tetrabenazine |
Emerging Therapies |
| Approval Year |
2017 |
2017 |
1979 |
Ongoing |
| Mechanism |
VMAT2 inhibitor |
VMAT2 inhibitor |
VMAT2 inhibitor |
Various; gene editing, receptor modulation |
| Indications |
TD primarily |
TD, HD, chorea |
Movement disorders |
Broad CNS indications |
| Dosage Form |
Oral |
Oral |
Oral |
Innovative delivery systems |
| Pricing (per month) |
USD 10,000 |
USD 8,500 |
USD 9,000 (generic) |
Varies |
Regulatory and Policy Trends Impacting Ingrezza
- FDA accelerated approval pathways expedite potential label expansions.
- Orphan drug designation for rare conditions provides market exclusivity and incentives.
- Healthcare policies emphasizing personalized medicine increase emphasis on clinical trial outcomes.
Key Takeaways
-
Clinical development continues to validate Ingrezza’s safety and expanding its therapeutic scope, particularly in complex movement disorders such as Tourette syndrome and Parkinson’s disease dyskinesia.
-
Market penetration remains robust, driven by unmet needs, pricing strategies, and broad reimbursement access in leading markets.
-
Competitive landscape favors Ingrezza as the first-in-class VMAT2 inhibitor, but patent expiries and generic entry pose long-term risks.
-
Future projections suggest the global market for Ingrezza and related therapies could reach USD 15 billion by 2030, supported by new indications, formulations, and expanding geographic reach.
-
Regulatory clarity and success in expanding indications are critical for sustaining growth and maximizing valuation.
FAQs
Q1: What are the main clinical advantages of Ingrezza over other VMAT2 inhibitors?
A1: Ingrezza has demonstrated a favorable safety profile, high selectivity, and once-daily dosing, which improve patient adherence and reduce side effects compared to tetrabenazine and deutetrabenazine.
Q2: How does patent expiry impact Ingrezza’s market outlook?
A2: Patent protection is expected until 2032, after which generic competitors can enter, likely leading to significant price reductions and erosion of market share unless new indications or formulations are approved.
Q3: Are there any ongoing efforts to extend Ingrezza’s use to pediatric populations?
A3: Yes, a Phase 4 pediatric study (NCT03270255) is completed, and submissions are anticipated to expand label indications, which could open new revenue streams.
Q4: What are the key risks that could inhibit Ingrezza’s growth?
A4: Potential challenges include patent challenges, the emergence of superior therapies, regulatory hurdles for new indications, and reimbursement restrictions in certain markets.
Q5: How do regulatory agencies impact the timeline of Ingrezza’s future expansion?
A5: Pending approval decisions from the FDA and EMA for new indications or formulations are critical; favorable reviews could accelerate market entry, while delays could impact revenue forecasts.
References
[1] Grand View Research, "Neurodegenerative Disease Treatment Market Size & Share," 2022.
[2] Neurocrine Biosciences SEC Filings, "Ingrezza (Valbenazine) Pricing and Reimbursement," 2022.
[3] ClinicalTrials.gov, "Ingrezza Clinical Trials," 2023.
[4] MarketWatch, "Global Movement Disorder Therapeutics Market," 2022.
[5] FDA Approval Notices & Public Health Announcements, 2017.
Note: All data and projections are based on publicly available information and market analyses as of Q1 2023. Future developments and regulatory decisions may significantly impact actual outcomes.
